A phase II, randomized, double-blind study to evaluate the effects of MEDI-522, a humanized MAb to integrin alpha V beta 3, on disease activity and progression of joint damage in pts with active rheumatoid arthritis suboptimally responding to methotrexate
Phase of Trial: Phase II
Latest Information Update: 26 Nov 2007
At a glance
- Drugs Etaracizumab (Primary)
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- 26 Nov 2007 Status changed from in progress to completed.
- 28 Oct 2005 New trial record.